Provided by Tiger Trade Technology Pte. Ltd.

Biohaven Pharmaceutical Holding Co Ltd.

12.07
+0.13501.13%
Volume:296.42K
Turnover:3.55M
Market Cap:1.81B
PE:-2.69
High:12.20
Open:11.86
Low:11.75
Close:11.93
52wk High:18.57
52wk Low:7.48
Shares:150.42M
Float Shares:117.99M
Volume Ratio:0.56
T/O Rate:0.25%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.4800
EPS(LYR):-6.8648
ROE:-799.46%
ROA:-71.98%
PB:148.48
PE(LYR):-1.76

Loading ...

Biohaven says BHV-1300 cuts Graves’ disease autoantibodies by over 80% in Phase 1b study

Reuters
·
May 27

Biohaven Reports Positive Clinical Biomarker and Patient Data: First Mode and Trap Extracellular Protein Degraders Achieve Deep, Rapid, Selective Lowering of Disease-Driving Antibodies in Graves' Disease and Iga Nephropathy

THOMSON REUTERS
·
May 27

Biohaven (BHVN) Is Up 20.0% After Promising Opakalim Epilepsy Data Release Has The Bull Case Changed?

Simply Wall St.
·
May 27

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Biohaven Ltd. (BHVN) and Immix Biopharma (IMMX)

TIPRANKS
·
May 27

Biohaven Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow Jones
·
May 27

Biohaven Gains After New Data From Epilepsy-Treatment Studies

Dow Jones
·
May 27

Biohaven reports data from selective Kv7.2/7.3 channel activator program

TIPRANKS
·
May 26

Biohaven says opakalim triples median time to second seizure day in idiopathic generalized epilepsy trial

Reuters
·
May 26

Biohaven Ltd - on Track for Top-Line Phase 2/3 Results in Refractory Focal Epilepsy in 2H 2026

THOMSON REUTERS
·
May 26

Biohaven Reports New Clinical Data in Epilepsy With Opakalim, a Selective Kv7.2/7.3 Activator, Highlighting Seizure Control and Markedly Differentiated Tolerability Profile

THOMSON REUTERS
·
May 26

Biohaven Ltd - Opakalim Prolongs Median Time to Second Seizure to 141 Days VS. 47 Days for Placebo

THOMSON REUTERS
·
May 26

Bank of America Securities Reaffirms Their Hold Rating on Biohaven Ltd. (BHVN)

TIPRANKS
·
May 22

Biohaven Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
May 14

Morgan Stanley Cuts Price Target on Biohaven to $18 From $21, Keeps Overweight Rating

MT Newswires Live
·
May 13

Biohaven (BHVN) Valuation Check After Q1 Results And New Shelf Registration

Simply Wall St.
·
May 12

Biohaven Warns of Broad Operational, Financial and Market Risks, Affirms Overall Risk Profile Matches Prior 10-K Disclosures

TIPRANKS
·
May 06

Biohaven launches USD 350 million at-the-market share offering program

Reuters
·
May 06

Stock Track | Biohaven Pharmaceutical Plummets 5.23% Intraday After Multiple Analyst Price Target Cuts

Stock Track
·
May 05

RBC Cuts Price Target on Biohaven to $22 From $23, Keeps Outperform, Speculative Risk

MT Newswires Live
·
May 05

Biohaven price target lowered to $12 from $14 at BofA

TIPRANKS
·
May 05